Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of weekly cagrilintide monotherapy and CagriSema in overweight or obese children and adolescents
CTR20262600Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of cagrilintide, semaglutide, CagriSema in obesity, Overweight, sponsored by Novo Nordisk. Started Aug 2026; status: active.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20262600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262600.